Biologicals targeting the PD-1/PD-L1 axis have been widely researched, and some antibodies have been approved by Food and Drug Administration (FDA) for certain cancer treatments, such as anti-PD-L1 antibody nivolumab [4], pembrolizumab [5], and anti-PD-L1 antibody atezolizumab avelumab. This evidence concerns the gene CD274 and cancer.